2024-02-28

LeadingTac: Leading the Targeted Protein Degradation Track to Make Global Innovative Innovative Drugs

2023-12-15

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi

2023-12-12

Big congratulations to Dr. Yan Feng of Leaddingtac was awarded with one of the first few of "Pearl Leading Talent" in Pudong New Area

2023-10-31

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi

2023-10-25

Leadingtac Announces CDE Approval of Phase I Clinical Trial for LT-002 for the treatment of Hidradenitis Suppurativa

2023-09-25

Kymera and its partner Sanofi announced plans to initiate a Phase 2 clinical trial of IRAK4 degrader KT474/SAR444656 in HS in the fourth quarter of 2023

2023-09-13

Leadingtac received the award "Shanghai 2023 technology innovation funds for small and medium-sized enterprises" project

2023-05-24

You may proceed！Leadingtac receives IND clearance to Conduct a Phase I study of LT-002, a world second-in-class IRAK4 degrader

2023-05-18

Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium

2023-04-18

Zhangjiang Science Investment Family｜Leadingtac: Contributing to China's New Drug Development in Zhangjiang